Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study

Figure 2

Transition to biosimilar infliximab: percentage of adult and pediatric patients with inflammatory bowel diseases who were previously treated with originator infliximab (brand name Remicade) and switched to biosimilar infliximab following the policy launch. The transition period of the Biosimilars Initiative started on 5 September 2019 and ended on 4 March 2020 for adults and on 15 May 2020 for pediatric patients. Patients with inflammatory bowel diseases were identified based on the algorithm presented in Supplementary Table 1 (policy cohort).